# A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes

> **NCT06881264** · PHASE3 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 401 (actual)

## Conditions studied

- Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs

## Interventions

- **DRUG:** HR17031 injection
- **DRUG:** insulin glargine

## Key facts

- **NCT ID:** NCT06881264
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-30
- **Primary completion:** 2025-09-19
- **Final completion:** 2025-09-19
- **Target enrollment:** 401 (ACTUAL)
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06881264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06881264, "A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06881264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*